Press coverage about Sinovac Biotech (NASDAQ:SVA) has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.158850485002 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Separately, BidaskClub raised Sinovac Biotech from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 30th.
SVA stock traded down $0.06 on Thursday, reaching $8.19. 7,281 shares of the company traded hands, compared to its average volume of 60,788. Sinovac Biotech has a one year low of $4.60 and a one year high of $8.75.
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.